在转移性透明细胞肾细胞癌患者使用 Nivolumab+Ipilimumab 后，比较卡博赞替尼和阿西替尼作为二线疗法的疗效：回顾性真实世界数据对比分析

IF 4.6 Q2 MATERIALS SCIENCE, BIOMATERIALS

ACS Applied Bio Materials Pub Date : 2024-06-01 DOI:10.1016/j.clgc.2024.102094

Ryotaro Tomida , Masayuki Takahashi , Yuto Matsushita , Takahiro Kojima , Kazutoshi Yamana , Shuya Kandori , Yukari Bando , Naotaka Nishiyama , Shimpei Yamashita , Hisanori Taniguchi , Keisuke Monji , Ryo Ishiyama , Shuichi Tatarano , Kimihiko Masui , Ayumu Matsuda , Tomoyuki Kaneko , Takanobu Motoshima , Yusuke Shiraishi , Satoru Kira , Takaya Murashima , Junya Furukawa

{"title":"在转移性透明细胞肾细胞癌患者使用 Nivolumab+Ipilimumab 后，比较卡博赞替尼和阿西替尼作为二线疗法的疗效：回顾性真实世界数据对比分析","authors":"Ryotaro Tomida , Masayuki Takahashi , Yuto Matsushita , Takahiro Kojima , Kazutoshi Yamana , Shuya Kandori , Yukari Bando , Naotaka Nishiyama , Shimpei Yamashita , Hisanori Taniguchi , Keisuke Monji , Ryo Ishiyama , Shuichi Tatarano , Kimihiko Masui , Ayumu Matsuda , Tomoyuki Kaneko , Takanobu Motoshima , Yusuke Shiraishi , Satoru Kira , Takaya Murashima , Junya Furukawa","doi":"10.1016/j.clgc.2024.102094","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>To date, no studies have compared the treatment outcomes of second-line therapies in patients with metastatic clear cell renal cell carcinoma (ccRCC). This study retrospectively evaluated the efficacy of cabozantinib and axitinib as second-line treatments in patients with metastatic ccRCC who previously received immune-oncology combination therapy.</p></div><div><h3>Patients and Methods</h3><p>Patients with metastatic ccRCC treated with cabozantinib and axitinib as second-line therapy after nivolumab-ipilimumab treatment were identified among 243 patients with RCC treated between August 1, 2018 and January 31, 2022 at 34 institutions belonging to the Japanese Urological Oncology Group. Patients were assessed for treatment outcomes, including progression-free survival (PFS), overall survival, objective response rate (ORR), and incidence rate of treatment-related adverse events (AEs).</p></div><div><h3>Results</h3><p>Forty-eight patients treated with cabozantinib and 60 treated with axitinib as second-line therapy after nivolumab-ipilimumab treatment for metastatic ccRCC were identified. The median PFS (95% confidence interval) was 11.0 months (9.0–16.0) with cabozantinib and 9.5 months (6.0–13.0) with axitinib. The ORRs were 37.5% (cabozantinib) and 38.3% (axitinib). The rates of any-grade AEs and grade ≥3 AEs were 79.2% (cabozantinib) versus 63.3% (axitinib; <em>P</em> = .091) and 35.4% (cabozantinib) versus 23.3% (axitinib; <em>P</em> = .202), respectively. In the poor-risk group, PFS was longer in the cabozantinib group than in the axitinib group (<em>P</em> = .033).</p></div><div><h3>Conclusion</h3><p>The efficacy and safety of cabozantinib and axitinib were comparable. In the poor-risk group, cabozantinib was more effective than axitinib. These findings provide valuable insights into the selection of second-line treatment options after nivolumab-ipilimumab treatment in patients with metastatic ccRCC.</p></div>","PeriodicalId":2,"journal":{"name":"ACS Applied Bio Materials","volume":null,"pages":null},"PeriodicalIF":4.6000,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Comparison of Cabozantinib and Axitinib as Second-line Therapy After Nivolumab Plus Ipilimumab in Patients With Metastatic Clear Cell Renal Cell Carcinoma: A Comparative Analysis of Retrospective Real-world Data\",\"authors\":\"Ryotaro Tomida , Masayuki Takahashi , Yuto Matsushita , Takahiro Kojima , Kazutoshi Yamana , Shuya Kandori , Yukari Bando , Naotaka Nishiyama , Shimpei Yamashita , Hisanori Taniguchi , Keisuke Monji , Ryo Ishiyama , Shuichi Tatarano , Kimihiko Masui , Ayumu Matsuda , Tomoyuki Kaneko , Takanobu Motoshima , Yusuke Shiraishi , Satoru Kira , Takaya Murashima , Junya Furukawa\",\"doi\":\"10.1016/j.clgc.2024.102094\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><p>To date, no studies have compared the treatment outcomes of second-line therapies in patients with metastatic clear cell renal cell carcinoma (ccRCC). This study retrospectively evaluated the efficacy of cabozantinib and axitinib as second-line treatments in patients with metastatic ccRCC who previously received immune-oncology combination therapy.</p></div><div><h3>Patients and Methods</h3><p>Patients with metastatic ccRCC treated with cabozantinib and axitinib as second-line therapy after nivolumab-ipilimumab treatment were identified among 243 patients with RCC treated between August 1, 2018 and January 31, 2022 at 34 institutions belonging to the Japanese Urological Oncology Group. Patients were assessed for treatment outcomes, including progression-free survival (PFS), overall survival, objective response rate (ORR), and incidence rate of treatment-related adverse events (AEs).</p></div><div><h3>Results</h3><p>Forty-eight patients treated with cabozantinib and 60 treated with axitinib as second-line therapy after nivolumab-ipilimumab treatment for metastatic ccRCC were identified. The median PFS (95% confidence interval) was 11.0 months (9.0–16.0) with cabozantinib and 9.5 months (6.0–13.0) with axitinib. The ORRs were 37.5% (cabozantinib) and 38.3% (axitinib). The rates of any-grade AEs and grade ≥3 AEs were 79.2% (cabozantinib) versus 63.3% (axitinib; <em>P</em> = .091) and 35.4% (cabozantinib) versus 23.3% (axitinib; <em>P</em> = .202), respectively. In the poor-risk group, PFS was longer in the cabozantinib group than in the axitinib group (<em>P</em> = .033).</p></div><div><h3>Conclusion</h3><p>The efficacy and safety of cabozantinib and axitinib were comparable. In the poor-risk group, cabozantinib was more effective than axitinib. These findings provide valuable insights into the selection of second-line treatment options after nivolumab-ipilimumab treatment in patients with metastatic ccRCC.</p></div>\",\"PeriodicalId\":2,\"journal\":{\"name\":\"ACS Applied Bio Materials\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":4.6000,\"publicationDate\":\"2024-06-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"ACS Applied Bio Materials\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S155876732400065X\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"MATERIALS SCIENCE, BIOMATERIALS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Applied Bio Materials","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S155876732400065X","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MATERIALS SCIENCE, BIOMATERIALS","Score":null,"Total":0}

引用次数: 0

摘要

背景迄今为止，还没有研究比较过转移性透明细胞肾细胞癌（ccRCC）患者二线疗法的治疗效果。本研究回顾性评估了卡博替尼和安希替尼作为既往接受过免疫肿瘤学联合疗法的转移性ccRCC患者二线治疗的疗效。患者和方法从2018年8月1日至2022年1月31日期间在日本泌尿肿瘤学组所属34家机构接受治疗的243名RCC患者中确定了在接受nivolumab-ipilimumab治疗后接受卡博替尼和安希替尼作为二线治疗的转移性ccRCC患者。对患者的治疗结果进行了评估，包括无进展生存期（PFS）、总生存期、客观应答率（ORR）以及治疗相关不良事件（AEs）的发生率。结果确定了48名患者在接受尼妥珠单抗-伊匹单抗治疗后接受卡博替尼治疗，60名患者接受阿西替尼治疗，作为转移性ccRCC的二线治疗。卡博替尼的中位PFS（95%置信区间）为11.0个月（9.0-16.0），阿西替尼为9.5个月（6.0-13.0）。ORR为37.5%（卡博赞替尼）和38.3%（阿昔替尼）。任何级别AE和≥3级AE的发生率分别为79.2%（卡博赞替尼）对63.3%（阿昔替尼；P = .091）和35.4%（卡博赞替尼）对23.3%（阿昔替尼；P = .202）。结论卡博替尼和安希替尼的疗效和安全性相当。在低风险组，卡博替尼比阿西替尼更有效。这些研究结果为转移性ccRCC患者在接受nivolumab-ipilimumab治疗后选择二线治疗方案提供了有价值的见解。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Comparison of Cabozantinib and Axitinib as Second-line Therapy After Nivolumab Plus Ipilimumab in Patients With Metastatic Clear Cell Renal Cell Carcinoma: A Comparative Analysis of Retrospective Real-world Data

Background

To date, no studies have compared the treatment outcomes of second-line therapies in patients with metastatic clear cell renal cell carcinoma (ccRCC). This study retrospectively evaluated the efficacy of cabozantinib and axitinib as second-line treatments in patients with metastatic ccRCC who previously received immune-oncology combination therapy.

Patients and Methods

Patients with metastatic ccRCC treated with cabozantinib and axitinib as second-line therapy after nivolumab-ipilimumab treatment were identified among 243 patients with RCC treated between August 1, 2018 and January 31, 2022 at 34 institutions belonging to the Japanese Urological Oncology Group. Patients were assessed for treatment outcomes, including progression-free survival (PFS), overall survival, objective response rate (ORR), and incidence rate of treatment-related adverse events (AEs).

Results

Forty-eight patients treated with cabozantinib and 60 treated with axitinib as second-line therapy after nivolumab-ipilimumab treatment for metastatic ccRCC were identified. The median PFS (95% confidence interval) was 11.0 months (9.0–16.0) with cabozantinib and 9.5 months (6.0–13.0) with axitinib. The ORRs were 37.5% (cabozantinib) and 38.3% (axitinib). The rates of any-grade AEs and grade ≥3 AEs were 79.2% (cabozantinib) versus 63.3% (axitinib; P = .091) and 35.4% (cabozantinib) versus 23.3% (axitinib; P = .202), respectively. In the poor-risk group, PFS was longer in the cabozantinib group than in the axitinib group (P = .033).

Conclusion

The efficacy and safety of cabozantinib and axitinib were comparable. In the poor-risk group, cabozantinib was more effective than axitinib. These findings provide valuable insights into the selection of second-line treatment options after nivolumab-ipilimumab treatment in patients with metastatic ccRCC.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

ACS Applied Bio Materials Chemistry-Chemistry (all)

CiteScore

9.40

自引率

2.10%

发文量

464